Personalized thromboprophylaxis using a risk score for the management of pregnancies with high risk of thrombosis: a prospective clinical study

被引:27
|
作者
Dargaud, Y. [1 ]
Rugeri, L. [1 ]
Fleury, C. [2 ]
Battie, C. [3 ]
Gaucherand, P. [3 ]
Huissoud, C. [4 ]
Rudigoz, R. C. [4 ]
Desmurs-Clavel, H. [5 ]
Ninet, J. [5 ]
Trzeciak, M. C. [1 ]
机构
[1] Hop Cardiovasc & Pneumol Louis Pradel, Unite Hemostase Clin, 28 Ave Doyen Jean Lepine, F-69500 Bron, France
[2] Hop Edouard Herriot, Lab Explorat Vascu, Pavillon M, Lyon, France
[3] Hop Femme Mere Enfant, Serv Obstet, Bron, France
[4] Hop Croix Rousse, Serv Obstet, Lyon, France
[5] CHU Lyon, Hop Edouard Herriot, Serv Med Interne, Pavillon O, Lyon, France
关键词
low molecular weight heparin; Lyon VTE score; pregnancy; prophylaxis; venous thromboembolism; VENOUS THROMBOEMBOLISM; ANTITHROMBOTIC THERAPY; WOMEN; THROMBOPHILIA; PREVENTION; POSTPARTUM; HEPARIN;
D O I
10.1111/jth.13660
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients with thrombophilia and/or a history of venous thromboembolism (VTE) are at risk of thrombosis during pregnancy. A risk score for pregnancies with an increased risk of VTE was previously described by our group (Lyon VTE score). Objectives: The aim of this prospective study was to assess the efficacy and safety of our score-based prophylaxis strategy in 542 pregnancies managed between 2005 and 2015 in Lyon University Hospitals. Patients/Methods: Of 445 patients included in the study, 36 had several pregnancies during the study period. Among these 445 patients, 279 had a personal history of VTE (62.7%), 299 patients (67.2%) had a thrombophilia marker, and 131 (29.4%) thrombophilic women had a personal history of VTE. During pregnancy, patients were assigned to one of three prophylaxis strategies according to the risk scoring system. Results: In the antepartum period, low molecular weight heparin (LMWH) prophylaxis was prescribed to 64.5% of patients at high risk of VTE. Among them, 34.4% were treated in the third trimester only, and 30.1% were treated throughout pregnancy. During the postpartum period, all patients received LMWH for at least 6 weeks. Two antepartum-related VTEs (0.37%; one with a score of < 3 and the other with a score of > 6) and four postpartum-related VTEs (0.73%; three with scores of 3-5 and one with a score of > 6) occurred. No case of pulmonary embolism was observed during the study period. The rate of bleeding was 0.37%. No serious bleeding requiring transfusions or surgery occurred during the study period. Conclusion: The use of a risk score may provide a rational decision process to implement safe and effective antepartum thromboprophylaxis in pregnant women at high risk of VTE.
引用
收藏
页码:897 / 906
页数:10
相关论文
共 50 条
  • [41] Clinical Predictive Factors of Lower Extremity Deep Vein Thrombosis in Relative High-Risk Patients after Neurosurgery: A Retrospective Study
    Li, Juhua
    Ren, XinZhen
    Zhu, Xiaole
    Chen, Huayu
    Lin, Zhen
    Huang, Mei
    Gu, Zejuan
    DISEASE MARKERS, 2020, 2020
  • [42] Screening high-risk cancer patients for VTE: A prospective observational study
    Khorana, Alok A.
    Rubens, Deborah
    Francis, Charles W.
    THROMBOSIS RESEARCH, 2014, 134 (06) : 1205 - 1207
  • [43] Peripartum outcomes of high-risk pregnancies complicated by oligo- and polyhydramnios: A prospective longitudinal study
    Magann, Everett F.
    Doherty, Dorota A.
    Lutgendorf, Monica A.
    Magann, Marcia I.
    Chauhan, Suneet P.
    Morrison, John C.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2010, 36 (02) : 268 - 277
  • [44] How Can Rotational Thromboelastometry as a Point-of-Care Method Be Useful for the Management of Secondary Thromboprophylaxis in High-Risk Pregnant Patients?
    Stanciakova, Lucia
    Dobrotova, Miroslava
    Holly, Pavol
    Zolkova, Jana
    Vadelova, Lubica
    Skornova, Ingrid
    Ivankova, Jela
    Bolek, Tomas
    Samos, Matej
    Grendar, Marian
    Danko, Jan
    Kubisz, Peter
    Stasko, Jan
    DIAGNOSTICS, 2021, 11 (05)
  • [45] High risk of long-term recurrence after a first episode of venous thromboembolism during pregnancy or postpartum: the REcurrence after a PrEgnAncy related Thrombosis (REPEAT) Study
    Ibrahim-Kosta, Manal
    El Harake, Sarah
    Leclercq, Barbara
    De Mari, Celine
    Secondi, Jean-Francois
    Paoletti, Emilie
    Suchon, Pierre
    Benredouane, Yasmine
    Brunet, Dominique
    Barthet, Marie-Christine
    Bruzelius, Maria
    Munsch, Gaelle
    Tregouet, David-Alexandre
    Morange, Pierre-Emmanuel
    Goumidi, Louisa
    Sarlon-Bartoli, Gabrielle
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2025, 23 (03) : 937 - 946
  • [46] A Prospective Observational Cohort of Clinical Outcomes in Medical Inpatients prescribed Pharmacological Thromboprophylaxis Using Different Clinical Risk Assessment Models(COMPT RAMs)
    Chamoun, Nibal
    Matta, Stephanie
    Aderian, Sandrine Sarine
    Salibi, Rami
    Salameh, Pascale
    Tayeh, Gaby
    Haddad, Elie
    Ghanem, Hady
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [47] Evaluation of guidelines for injured children at high risk for venous thromboembolism: A prospective observational study
    Landisch, Rachel M.
    Hanson, Sheila J.
    Cassidy, Laura D.
    Braun, Kristin
    Punzalan, Rowena C.
    Gourlay, David M.
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2017, 82 (05) : 836 - 844
  • [48] Pica and Eating Attitudes: A Study of High-Risk Pregnancies
    Amanda M. Santos
    Gláucia R. G. Benute
    Roseli M. Y. Nomura
    Niraldo O. Santos
    Mara C. S. De Lucia
    Rossana P. V. Francisco
    Maternal and Child Health Journal, 2016, 20 : 577 - 582
  • [49] Clinical analysis of bleeding and thrombotic events in haematological-oncology patients with severe thrombocytopenia and a high risk of thrombosis
    Wang, Jing
    Gou, Min
    Xu, Fang
    Chen, Bin
    Wang, Shu
    Shi, Qiumei
    Li, Qiuling
    Yu, Jing
    Zhang, Lan
    Yang, Meiqi
    Tang, Jiao
    Yan, Die
    Xiao, Yan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [50] Optimizing the Personalized, Risk-Adjusted Management of Pulmonary Embolism: An Integrated Clinical Trial Programme
    Barco, Stefano
    Konstantinides, Stavros, V
    HAMOSTASEOLOGIE, 2019, 39 (02): : 117 - 127